Industry News
CogState signs $400,000 functional food deal
CogState (ASX:CGS) is to provide cognition testing services to a European food products company in a contract worth more than AUD$400,000. [ + ]
Pharmaxis earns regulatory thumbs-up for Aridol
The Australian Drug Evaluation Committee has recommended to the TGA that Sydney-based drug developer Pharmaxis' (ASX:PXS) first product, the asthma diagnostic and treatment management tool Aridol, be registered for sale in Australia. [ + ]
Analytica chairman defends cash position
The ASX has issued a 'please explain' to Brisbane-based Analytica (ASX:ALT), querying whether the company will have enough cash to last it past the next quarter. [ + ]
Cost-effective screening for SCID
Two UCLA studies have shown that newborn screening for Severe Combined Immunodeficiency (SCID) a rare, treatable disorder of the immune system commonly known as 'bubble boy disease' is both cost-effective and could be done accurately using a two tiered testing method.
[ + ]Ovarian cancer diagnostic test
Proteome Systems has announced a collaboration with Prince Henry's Institute Medical Research (PHIMR) to combine their IP and expertise in ovarian cancer for the discovery and development of novel diagnostic markers.
[ + ]Novartis, Bausch & Lomb to promote pSivida blindness treatment
Perth-based bio-nanotech company pSivida's (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) Retisert will be co-promoted in the US by Novartis Ophthalmics. [ + ]
Solagran's liver treatment 'fast tracked' in Russia
Melbourne-base Solagran has been granted Russian approval to register Ropren, the finished form of Bioeffective R, as a new medicine for the treatment for chronic liver disease. [ + ]
Biotech Capital reduces stake in C3
BioTech Capital (ASX:BTC) has reduced its shareholding in Clinical Cell Culture (ASX:CCE, C3) from about 19 per cent to 12 per cent. [ + ]
BrainZ expands US operations
Auckland-based BrainZ (ASX:BZI) has established its US clinical support team and headquarters. [ + ]
Blood test for early identification of colon cancer
Researchers have developed a blood test that detects the presence of fragments of mutated genes that are present in colon cancer cells. Their pilot studies provide the basis for diagnostic assays for cancer that could allow physicians to detect rumours at an early stage.
[ + ]DotScan helps join the dots in identifying heart disease
University of Sydney researchers claim to have achieved almost perfect discrimination between two major forms of heart disease from patients' blood samples, using Sydney firm Medsaic's proprietary DotScan technology. [ + ]
Stirling study shows reduced weight gain in rats
A study conducted for Perth-based Stirling Products (ASX:STI) has shown that its beta agonist ST810 reduced weight gain in obese Zucker rats. [ + ]
In brief: Benitec, Biota, Eqitx
Benitec (ASX:BLT) has appointed former Axon Instruments VP Michael Catelani as executive director and Boron Molecular founder Peter Francis as non-executive director. [ + ]
Alchemia's synthetic heparin completes pilot scale process
The first batch of Brisbane biopharma Alchemia's (ASX:ACL) synthetic heparin has completed purification -- the final stage of the pilot scale process development -- at the US facilities of the company's manufacturing partner, The Dow Chemical Company. [ + ]
National bioinformatics network gathers speed
A national bioinformatics network has been established following a $2.2 million grant from the National Health and Medical Research Council of Australia. [ + ]
